Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Rheumatoid Arthritis
•
Methotrexate
•
General Rheumatology
What is your approach to methotrexate use (or avoidance) in patients with varying MTHFR mutations?
Related Questions
Do you always get a baseline chest xray in patients who will be starting methotrexate?
What is your approach to diagnosing and managing methotrexate-induced alopecia?
How do you manage transaminitis in a patient receiving TNF alpha inhibitors?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
How do you approach patients who identify so strongly with being sick or with a particular diagnostic label that it makes up a significant portion of their identity?
Do you continue PJP prophylaxis indefinitely in patients on rituximab maintenance therapy?
Can lupus anticoagulant be positive despite a normal aPTT?
How do you approach the treatment of patients with Ehlers-Danlos hypermobile type with chronic muscle spasms with minimal exertion?
How do you approach treatment intensification in patients with RA and low disease activity but not in remission, considering the potential risks of increased immunosuppression?
When trying to increase infliximab for active disease (inflammatory arthritis or sarcoidosis), do you prefer to increase dosage or reduce frequency between doses?
